Rigel Pharmaceuticals
RIGL
117 hedge funds and large institutions have $490M invested in Rigel Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 19 closing their positions.
73% more call options, than puts
Call options by funds: $8.8M | Put options by funds: $5.09M
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
0.12% more ownership
Funds ownership: 9.29% → 9.41% (+0.12%)
3% less funds holding
Funds holding: 121 → 117 (-4)
7% less capital invested
Capital invested by funds: $528M → $490M (-$37.5M)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$8.01M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.04M |
| 3 |
Citigroup
New York
|
+$3.25M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.77M |
| 5 |
JP Morgan Chase
New York
|
+$2.61M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$6.27M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.67M |
| 3 |
SCM
Sio Capital Management
New York
|
-$3.43M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.95M |
RIGL Hedge Fund Activity: Q1 2018 in Review
117 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2018, worth a combined $490M — down 7.1% from $528M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RIGL and 16 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 44 added.
The largest buyer was Boxer Capital, adding an estimated $8.01M. The largest seller was Millennium Management, cutting an estimated $6.27M.
- 117 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2018, down from 121 in Q4 2017.
- Funds reported $490M of Rigel Pharmaceuticals stock for Q1 2018, down 7.1% quarter-over-quarter.
- 16 funds opened new Rigel Pharmaceuticals positions in Q1 2018 and 19 closed out, a net change of -3 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2018 was Boxer Capital, an estimated $8.01M added.
- The largest Rigel Pharmaceuticals seller in Q1 2018 was Millennium Management, an estimated $6.27M sold.
Based on aggregated 13F filings for Q1 2018.